News

Cancel
  • Currently, there are no effective drugs available to fight SARS coronavirus-2 (SARS-CoV-2) and the associated disease, COVID-19. The working group on High-Throughput Drug and Target Discovery at Fraunhofer ITEM in Regensburg is cooperating with partners from the University of Regensburg and the company 2bind GmbH, aiming to identify drug candidates that specifically inhibit packaging of the SARS-CoV-2 genome into virus particles and thereby prevent replication of the virus. The project will be funded by the Bavarian Research Foundation for a period of one year, starting in December 2020.

    more info
  • "Press release by CORAT Therapeutics on November 18, 2020" / 2020

    Human antibody against COVID-19 ready for clinical trials

    November 18, 2020

    CORAT Therapeutics CEO Dr. Andreas Herrmann today announced the completion of the production campaign of the first major batch of COR-101, which is now available for clinical trials. COR-101 is a fully human antibody developed in Braunschweig, Germany, which efficiently blocks the cell entry of SARS-CoV-2 and thus prevents the proliferation of coronaviruses.

    more info
  • As a pioneer in applied research, the Fraunhofer-Gesellschaft is bringing together the expertise of 23 Fraunhofer institutions to develop new development and production technologies for innovative cell and gene therapeutics, as well as vaccines, in the “Production for Intelligent Medicine” innovation cluster.

    more info
  • Disinfectants play an important role in preventing infectious diseases. The outbreak of the COVID-19 pandemic resulted in an increased need of disinfectants with at least "limited virucidal" activity, i.e. substances that are effective against enveloped viruses such as SARS-CoV-2. Disinfectants are biocidal products and the quantity of biocidal products authorized in the EU until March 2020 turned out to be insufficient.

    more info